The active ingredient of marijuana is (−)-Δ 9-tetrahydrocannabinol (Δ 9-THC). Δ 9-THC and
other natural and synthetic cannabinoids such as CP-55, 940 inhibit spontaneous activity …

Specific cannabinoid receptors have been recently described in extrapyramidal and limbic
areas and presumably might mediate the effects of marijuana exposure on behavioral …

USING in situ hybridization we found that chronic treatment with CP-55,940 (0.4 mg kg− 1, ip
daily for 11 days), a synthetic cannabinoid receptor ligand, changed cannabinoid receptor …

Recent studies have demonstrated that the pharmacological tolerance observed after
prolonged exposure to plant or synthetic cannabinoids in adult individuals seems to have a …

A brain constituent, the N-amide derivative of arachidonic acid, termed anandamide, has
been recently proposed as a possible endogenous ligand for the cannabinoid receptor. The …

Previous data showed the development of tolerance to a variety of pharmacological effects
of plant and synthetic cannabinoids when administered chronically. This tolerance …

The effect of repetitive administration of delta-9-tetrahydrocannabinol (Δ 9-THC) in mice on
behavioral and biochemical tolerance was determined in this study. Mice were injected …

The effects of chronic Δ9-tetrahydrocannabinol on cannabinoid receptor levels and receptor–
G-protein coupling were investigated. Male Sprague–Dawley rats were infused continuously …

The receptor occupancy required to produce cannabinoid effects in the central nervous
system was determined in both a neurochemical and a behavioral assay for cannabinoid …

Chronic treatment of rats with▵ 9‐tetrahydrocannabinol (▵ 9‐THC) results in tolerance to its
acute behavioral effects. In a previous study, 21‐day▵ 9‐THC treatment in rats decreased …